For help on how to get the results you want, see our search tips.
756 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Orphan designations Remove Orphan designations filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Categories
Human Remove Human filter
PIP decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) Remove RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter
PM: decision on the application for modification of an agreed PIP Remove PM: decision on the application for modification of an agreed PIP filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): peginesatide
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-000646-PIP01-09-M01, Route(s) of administration: Intravenous and subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 24/10/2012, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): lucerastat
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-002095-PIP01-16-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Age-appropriate oral solid paediatric formulation
Decision date: 17/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Human fibrinogen concentrate (BT524)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001931-PIP01-16-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution for injection or infusion
Decision date: 19/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ligelizumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: EMEA-001811-PIP02-15-M03, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 16/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology, Immunology-Rheumatology-Transplantation
PIP number: EMEA-001741-PIP04-17-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Age-appropriate oral liquid dosage form, Age-appropriate oral solid dosage form, Prolonged-release capsule, Prolonged-release tablet
Decision date: 17/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Alofisel, darvadstrocel
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001561-PIP01-13-M01, Route(s) of administration: Intralesional use, Pharmaceutical form(s): Suspension for injection
Decision date: 16/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-001664-PIP02-15-M04, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for injection
Decision date: 19/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): satralizumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-001625-PIP01-14-M05, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 16/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): anifrolumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-001435-PIP02-16-M01, Route(s) of administration: Intravenous use, Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 16/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): outer membrane vesicles (OMV) from n. meningitidis strain NZ 98/254, recombinant neisseria meningitis group B Protein 936-741, meningococcal group W-135 oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein, meningococcal group A oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein, meningococcal group C oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein, recombinant neisseria meningitis group B Protein 287-953, recombinant neisseria meningitis group B Protein 961c, meningococcal group Y oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein (MenABCWY)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-001260-PIP01-11-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Powder and suspension for suspension for injection
Decision date: 19/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Adcetris, Brentuximab vedotin
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000980-PIP01-10-M06, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion
Decision date: 22/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-000576-PIP01-09-M12, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Prolonged-release film-coated tablet, Oral solution, Prolonged-release age-appropriate oral formulation
Decision date: 17/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Brilique, ticagrelor
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases, Haematology-Hemostaseology
PIP number: EMEA-000480-PIP01-08-M13, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Granules for oral suspension, Orodispersible tablet
Decision date: 17/06/2020, Last updated: 17/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Briviact (in Italy: Nubriveo), Brivaracetam
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-000332-PIP02-17-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Oral solution
Decision date: 12/06/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Maralixibat chloride (LUM001)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001475-PIP03-17-M02, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution
Decision date: 25/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Imlygic, talimogene laherparepvec
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001251-PIP01-11-M04, Route(s) of administration: Intratumoral use, Pharmaceutical form(s): Solution for injection
Decision date: 13/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Genvoya, elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001460-PIP01-13-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 27/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Evenity, Romosozumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001075-PIP04-15-M02, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 15/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tecfidera, dimethyl fumarate
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-000832-PIP01-10-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 15/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): 2-iminobiotin
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neonatology-Paediactric Intensive care
PIP number: EMEA-001070-PIP01-10-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for infusion
Decision date: 15/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Trulicity, dulaglutide
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-000783-PIP01-09-M05, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection (pre-filled pen)
Decision date: 13/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Aflunov, Influenza virus surface antigens - A/turkey/Turkey/1/05 (H5N1)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-000599-PIP01-09-M07, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension for injection
Decision date: 15/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Methoxyflurane
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Pain
PIP number: EMEA-000334-PIP01-08-M09, Route(s) of administration: Inhalation use, Pharmaceutical form(s): Inhalation vapour, liquid
Decision date: 13/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Eliquis, Apixaban
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000183-PIP01-08-M08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral liquid dosage form, Age-appropriate dosage form, other
Decision date: 20/05/2020, Last updated: 16/03/2021, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Eliquis, Apixaban
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000183-PIP02-12-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral liquid dosage form, Age-appropriate dosage form, other
Decision date: 20/05/2020, Last updated: 16/03/2021, Compliance check: X